Literature DB >> 4040567

Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat.

F F Farris, F G King, R L Dedrick, C L Litterst.   

Abstract

A physiological model has been developed to describe the disposition of cis-dichlorodiammine-platinum(II) (DDP) following i.v. dosing in the female rat bearing the Walker 256 carcinoma. The model simulates concentrations of DDP and its mobile and fixed metabolites in plasma, liver, gut, skin, muscle, tumor, carcass, and kidney, and DDP and mobile metabolite excretion following a 4 mg/kg dose. In the kinetic model, DDP binds irreversibly to low MW nucleophiles and macromolecules (largely proteins) within the plasma and tissue compartments to form mobile and fixed metabolites, respectively. Reaction rates for the formation of each metabolite are tissue/organ specific. The rate constant for the biotransformation of DDP to fixed metabolite in plasma (k2P = 0.0082 min-1) was determined from in vitro incubation studies. This rate was used as the basis for estimating the biotransformation rate constants for DDP to fixed and mobile metabolites in other compartments. Both DDP and mobile metabolite are assumed to follow flow-limited transport, to freely traverse compartmental barriers, and to partition equally in all compartments. Both are excreted in the urine, the major route of Pt elimination. Urinary excretion is modeled as a linear process involving filtration only; an assumption based on a calculated renal clearance of 1.1 ml/min, a value very similar to the estimated GFR. Biliary excretion is a minor route of mobile metabolite elimination and is modeled as a linear process occurring in the liver. Four hours after dosing, approximately 60% of the administered Pt remains in the tissues and plasma. Of this, over 75% of the plasma Pt and 90% of the metal ion in every other compartment is fixed (protein bound). Fixed Pt can be eliminated from a compartment only after its biotransformation to mobile metabolite. In most compartments this rate of elimination corresponds closely to the average rate of protein turnover in that compartment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4040567     DOI: 10.1007/bf01073654

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  44 in total

Review 1.  cis-Diamminedichloroplatinum(II): a metal complex with significant anticancer activity.

Authors:  D D Von Hoff; M Rozencweig
Journal:  Adv Pharmacol Chemother       Date:  1979

2.  Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent.

Authors:  J Sedlak; R H Lindsay
Journal:  Anal Biochem       Date:  1968-10-24       Impact factor: 3.365

3.  Complexes of serum albumin and cis-dichlorodiammineplatinum (II). The role of cysteine 34 as a nucleophilic entering group and evidence for reaction between bound platinum and a second macromolecule.

Authors:  S L Gonias; S V Pizzo
Journal:  J Biol Chem       Date:  1983-05-10       Impact factor: 5.157

4.  Blood flow and heat transfer in Walker 256 mammary carcinoma.

Authors:  R K Jain; F H Grantham; P M Gullino
Journal:  J Natl Cancer Inst       Date:  1979-04       Impact factor: 13.506

5.  Bone marrow sulphydryl levels.

Authors:  G Calcutt
Journal:  Nature       Date:  1966-07-09       Impact factor: 49.962

6.  Role of renal cortical sulfhydryl groups in development of mercury-induced renal toxicity.

Authors:  D R Johnson
Journal:  J Toxicol Environ Health       Date:  1982-01

7.  Levels of sulfhydryls and sulfhydryl-containing enzymes in brain, liver and testis of manganese treated rats.

Authors:  G S Shukla; S V Chandra
Journal:  Arch Toxicol       Date:  1977-08-09       Impact factor: 5.153

8.  Effect of probenecid and N'-methylnicotinamide on renal handling of cis-dichlorodiammineplatinum-II in rats.

Authors:  N M Osman; C L Litterst
Journal:  Cancer Lett       Date:  1983-05       Impact factor: 8.679

9.  Effect of a forced diuresis on the distribution and excretion (via urine and bile) of 195mplatinum when given as 195mplatinum cis-dichlorodiammineplatinum(II).

Authors:  P A DeSimone; R S Yancey; J J Coupal; J D Butts; J D Hoeschel
Journal:  Cancer Treat Rep       Date:  1979-06

10.  Pharmacokinetic modeling of cisplatin disposition in children and adolescents with cancer.

Authors:  W E Evans; W R Crom; A Tsiatis; A A Green; F A Hayes; C B Pratt
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

View more
  7 in total

1.  Clinical pharmacokinetics of 3-day continuous infusion cisplatin and daily bolus 5-fluorouracil.

Authors:  J F Belliveau; M R Posner; G W Crabtree; A B Weitberg; M C Wiemann; F J Cummings; G P O'Leary; E Ingersoll; P Calabresi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Physiological modeling of drug and metabolite: disposition of oxazepam and oxazepam glucuronides in the recirculating perfused mouse liver preparation.

Authors:  M V St-Pierre; D van den Berg; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

3.  Physiological pharmacokinetic parameters for cis-dichlorodiammineplatinum(II) (DDP) in the mouse.

Authors:  F G King; R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1992-02

4.  Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.

Authors:  K Hanada; K Odaka; A Kudo; H Ogata
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

5.  Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.

Authors:  F G King; R L Dedrick; F F Farris
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

6.  Effect of tumor presence on cisplatin and carboplatin: disposition in the isolated, perfused tumor and skin flap.

Authors:  S L Vaden; P L Williams; R L Page; J E Riviere
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.

Authors:  D C Thompson; A Vaisman; M K Sakata; S D Wyrick; D J Holbrook; S G Chaney
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.